A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone
Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for conversion to psychosis states have had variable, and often negative, results. To examine adjunctive omega-3 treatment for recent onset psychosis, participants aged 15 –40 years with recent onset schizophrenia-spectrum (n = 46) or bipolar (n = 4) disorders and current psychotic symptoms were treated for 16 weeks with risperidone and randomly-assigned omega-3 (EPA 740 mg and DHA 400 mg daily) or matching placebo. The primary outcome measure was th e Brief Psychiatric Rating Scale (BPRS) total score.
Source: Schizophrenia Research - Category: Psychiatry Authors: Delbert G. Robinson, Juan A. Gallego, Majnu John, Lauren A. Hanna, Jian-Ping Zhang, Michael L. Birnbaum, Jessica Greenberg, Melissa Naraine, Bart D. Peters, Robert K. McNamara, Anil K. Malhotra, Philip R. Szeszko Source Type: research
More News: Anxiety | Bipolar | Depression | Lovaza | Mania | Omega 3 | Psychiatry | Risperdal Consta | Schizophrenia | Study